Curis News - CRIS

Company Name	Stock Ticker Symbol	Market	Type
Curis Inc	CRIS	NASDAQ	Common Stock

	Price Change	Change Percent	Stock Price	Last Traded
	-0.1552	-1.07%	14.3648	14:33:04

Open Price	Low Price	High Price	Close Price	Prev Close
14.44	14.25	14.689		14.52

more quote information »

Recent News

Date	Time	Source	Heading
4/05/2024	07:30	PRNUS	Curis Reports Inducement Grants Under NASDAQ Listing Rule..
4/04/2024	07:30	PRNUS	Curis to Present at Upcoming Healthcare Conferences in April
2/12/2024	16:16	EDGAR2	Form SC 13G - Statement of acquisition of beneficial..
2/08/2024	16:36	EDGAR2	Form S-8 - Securities to be offered to employees in employee..
2/08/2024	16:27	EDGAR2	Form S-3 - Registration statement under Securities Act of..
2/08/2024	16:01	EDGAR2	Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2/08/2024	08:01	EDGAR2	Form 8-K - Current report
2/08/2024	08:00	PRNUS	Curis Provides Fourth Quarter 2023 Business Update
2/01/2024	08:00	PRNUS	Curis to Release Fourth Quarter 2023 Financial Results and..
1/11/2024	08:13	EDGAR2	Form 8-K - Current report
1/05/2024	08:00	PRNUS	Curis Reports Inducement Grants Under NASDAQ Listing Rule..
12/21/2023	16:00	EDGAR2	Form 10-K/A - Annual report [Section 13 and 15(d), not S-K..
12/12/2023	08:00	PRNUS	Curis Announces Initial Combination Study Data from its..
12/11/2023	08:00	PRNUS	Curis Presented Clinical Data from the TakeAim Leukemia..
12/06/2023	08:00	PRNUS	Curis Announces Three Presentations at ASH
12/05/2023	08:00	PRNUS	Curis Enters into Agreement for Emavusertib / Pembrolizumab..
11/02/2023	08:03	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/02/2023	08:01	EDGAR2	Form 8-K - Current report
11/02/2023	08:00	PRNUS	Curis Provides Third Quarter 2023 Business Update
10/26/2023	08:30	PRNUS	Curis to Release Third Quarter 2023 Financial Results and..
10/06/2023	08:56	PRNUS	Curis Reports Inducement Grants Under NASDAQ Listing Rule..
9/28/2023	16:05	EDGAR2	Form 8-K/A - Current report: [Amend]
9/28/2023	08:54	EDGAR2	Form 8-K - Current report
9/12/2023	08:00	PRNUS	Curis Announces Date for the 2nd Symposium on IRAK4 in..
9/06/2023	08:13	PRNUS	Curis to Present at Upcoming Healthcare Conferences in..
8/18/2023	16:02	EDGAR2	Form DEF 14A - Other definitive proxy statements
8/04/2023	16:09	EDGAR2	Form PRE 14A - Other preliminary proxy statements
8/03/2023	16:04	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/03/2023	16:02	EDGAR2	Form 8-K - Current report
8/03/2023	16:01	PRNUS	Curis Provides Second Quarter 2023 Business Update
7/27/2023	18:25	PRNUS	Curis to Release Second Quarter 2023 Financial Results and..
7/06/2023	16:30	EDGAR2	Form 424B5 - Prospectus [Rule 424(b)(5)]
7/06/2023	09:28	EDGAR2	Form 8-K - Current report
7/06/2023	08:04	EDGAR2	Form 8-K - Current report
7/06/2023	08:01	PRNUS	FDA Removes Partial Clinical Hold on TakeAim Leukemia Study..
7/06/2023	08:00	PRNUS	Curis Announces $15.1 Million Registered Direct Offering
5/05/2023	07:30	PRNUS	Curis Reports Inducement Grants Under NASDAQ Listing Rule..
5/04/2023	16:01	PRNUS	Curis Provides First Quarter 2023 Business Update
4/27/2023	16:01	PRNUS	Curis to Release First Quarter 2023 Financial Results and..